Association/NN
Study/NN
between/IN
Folate/NN
Pathway/NN
Gene/NN
Single/JJ
Nucleotide/JJ
Polymorphisms/NNS
and/CC
Gastric/JJ
Cancer/NN
in/IN
Koreans/NNS
./.
====================
Gastric/JJ
cancer/NN
is/VBZ
ranked/VBN
as/IN
the/DT
most/JJS
common/JJ
cancer/NN
in/IN
Koreans/NNS
./.
====================
A/DT
recent/JJ
molecular/JJ
biological/JJ
study/NN
about/IN
the/DT
folate/JJ
pathway/NN
gene/NN
revealed/VBD
the/DT
correlation/NN
with/IN
a/DT
couple/JJ
of/IN
cancer/NN
types/NNS
./.
====================
In/IN
the/DT
folate/JJ
pathway/NN
,/,
several/JJ
genes/NNS
are/VBP
involved/VBN
,/,
including/VBG
methylenetetrahydrofolate/JJ
reductase/NN
(/(
MTHFR/NN
)/)
,/,
methyltetrahydrofolate-homocysteine/NN
methyltransferase/NN
reductase/NN
(/(
MTRR/NN
)/)
,/,
and/CC
methyltetrahydrofolate-homocysteine/NN
methyltransferase/NN
(/(
MTR/NN
)/)
./.
====================
The/DT
MTHFR/NN
gene/NN
has/VBZ
been/VBN
reported/VBN
several/JJ
times/NNS
for/IN
the/DT
correlation/NN
with/IN
gastric/JJ
cancer/NN
risk/NN
./.
====================
However/RB
,/,
the/DT
association/NN
of/IN
the/DT
MTRR/NN
or/CC
MTR/NN
gene/NN
has/VBZ
not/RB
been/VBN
reported/VBN
to/TO
date/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
investigated/VBD
the/DT
association/NN
between/IN
the/DT
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
of/IN
the/DT
MTHFR/NN
,/,
MTRR/NN
,/,
and/CC
MTR/NN
genes/NNS
and/CC
the/DT
risk/NN
of/IN
gastric/JJ
cancer/NN
in/IN
Koreans/NNS
./.
====================
To/TO
identify/VB
the/DT
genetic/JJ
association/NN
with/IN
gastric/JJ
cancer/NN
,/,
we/PRP
selected/VBD
17/CD
SNPs/NNS
sites/NNS
in/IN
folate/JJ
pathway-associated/JJ
genes/NNS
of/IN
MTHFR/NN
,/,
MTR/NN
,/,
and/CC
MTRR/NN
and/CC
tested/VBN
in/IN
1,261/CD
gastric/JJ
cancer/NN
patients/NNS
and/CC
375/CD
healthy/JJ
controls/NNS
./.
====================
By/IN
genotype/NN
analysis/NN
,/,
estimating/VBG
odds/NNS
ratios/NNS
and/CC
95/CD
%/NN
confidence/IN
intervals/NNS
(/(
CI/NN
)/)
,/,
rs1801394/NN
in/IN
the/DT
MTRR/NN
gene/NN
showed/VBD
increased/VBN
risk/NN
for/IN
gastric/JJ
cacner/NN
,/,
with/IN
statistical/JJ
significance/NN
both/CC
in/IN
the/DT
codominant/JJ
model/NN
(/(
odds/NNS
ratio/NN
[/(
OR/NN
]/)
,/,
1.39/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.04/CD
to/TO
1.85/CD
)/)
and/CC
dominant/JJ
model/NN
(/(
OR/NN
,/,
1.34/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.02/CD
to/TO
1.75/CD
)/)
./.
====================
Especially/RB
,/,
in/IN
the/DT
obese/JJ
group/NN
(/(
body/NN
mass/NN
index/NN
≥/CD
25/CD
kg/m2/NN
)/)
,/,
the/DT
codominant/JJ
(/(
OR/NN
,/,
9.08/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.01/CD
to/TO
94.59/CD
)/)
and/CC
recessive/JJ
model/NN
(/(
OR/NN
,/,
3.72/CD
;/:
95/CD
%/NN
CI/NN
,/,
0.92/CD
to/TO
16.59/CD
)/)
showed/VBD
dramatically/RB
increased/VBD
risk/NN
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
In/IN
conclusion/NN
,/,
rs1801394/NN
in/IN
the/DT
MTRR/NN
gene/NN
is/VBZ
associated/VBN
with/IN
gastric/JJ
cancer/NN
risk/NN
,/,
and/CC
its/PRP$
functional/JJ
significance/NN
need/VBD
to/TO
be/VB
validated/VBN
./.
====================
According/VBG
to/TO
the/DT
Korea/NN
Central/JJ
Cancer/NN
Registry/NN
data/NNS
,/,
gastric/JJ
cancer/NN
is/VBZ
ranked/VBN
as/IN
the/DT
most/JJS
common/JJ
cancer/NN
in/IN
Korean/JJ
and/CC
men/NNS
and/CC
accounted/VBN
for/IN
about/RB
20.1/CD
%/NN
of/IN
all/DT
cancers/NNS
in/IN
Koreans/NNS
./.
====================
In/IN
Korea/NN
,/,
29,727/NN
cases/NNS
of/IN
gastric/JJ
cancer/NN
were/VBD
newly/RB
diagnosed/VBN
,/,
and/CC
the/DT
crude/JJ
incidence/NN
rate/NN
of/IN
gastric/JJ
cancer/NN
in/IN
2009/CD
was/VBD
59.9/CD
per/FW
100,000/CD
./.
====================
In/IN
males/NNS
,/,
the/DT
number/NN
of/IN
newly/RB
diagnosed/VBN
cases/NNS
and/CC
incidence/NN
rates/NNS
of/IN
stomach/NN
cancer/NN
in/IN
2009/CD
were/VBD
19,953/CD
cases/NNS
and/CC
80.2/CD
per/FW
100,000/CD
,/,
respectively/RB
./.
====================
The/DT
5-year/JJ
relative/JJ
survival/NN
rates/NNS
of/IN
gastric/JJ
cancers/NNS
were/VBD
increased/VBN
by/IN
22.5/CD
%/NN
from/IN
42.8/CD
%/NN
in/IN
1993-1995/CD
to/TO
65.3/CD
%/NN
in/IN
2005-2009/CD
[/(
1/CD
]/)
./.
====================
Evidence/NN
from/IN
pathology/NN
and/CC
epidemiology/NN
studies/NNS
has/VBZ
provided/VBN
a/DT
human/JJ
model/NN
of/IN
gastric/JJ
carcinogenesis/NN
with/IN
the/DT
following/VBG
sequential/JJ
stages/NNS
:/:
chronic/JJ
gastritis/NN
;/:
atrophic/JJ
gastritis/NN
;/:
intestinal/JJ
metaplasia/NN
;/:
and/CC
dysplasia/NN
[/(
2/CD
]/)
./.
====================
Also/RB
,/,
an/DT
environmental/JJ
element/NN
of/IN
gastric/JJ
cancer/NN
occurrence/NN
exists/VBZ
plentifully/RB
./.
====================
The/DT
best/JJS
well-known/JJ
risk/NN
factors/NNS
for/IN
gastric/JJ
cancer/NN
are/VBP
Helicobacter/JJ
pylori/NN
infection/NN
,/,
by/IN
far/RB
the/DT
strongest/JJS
established/VBN
risk/NN
factor/NN
for/IN
gastric/JJ
cancer/NN
;/:
a/DT
family/NN
history/NN
;/:
and/CC
smoking/NN
./.
====================
Several/JJ
factors/NNS
related/JJ
to/TO
nutrition/NN
and/CC
food/NN
preservation/NN
,/,
such/JJ
as/IN
high/JJ
intake/NN
of/IN
salt-preserved/JJ
foods/NNS
and/CC
dietary/JJ
nitrite/JJ
or/CC
low/JJ
intake/JJ
of/IN
fruit/JJ
and/CC
vegetables/NNS
,/,
are/VBP
likely/JJ
to/TO
increase/VB
the/DT
risk/NN
of/IN
gastric/JJ
cancer/NN
[/(
3/CD
]/)
./.
====================
Cancerogenesis/NN
,/,
which/WDT
is/VBZ
the/DT
loss/NN
of/IN
cellular/JJ
differentiation/NN
that/DT
leads/VBZ
the/DT
digestive/JJ
tract/VBP
to/TO
cancer/NN
,/,
is/VBZ
inhibited/VBN
by/IN
nutrition/NN
factors/NNS
,/,
such/JJ
as/IN
retinoid/JJ
,/,
vitamins/FW
B-complex/NN
(/(
including/VBG
folate/JJ
)/)
,/,
vitamin/NN
C/NN
,/,
D3/NN
,/,
and/CC
E/NN
,/,
polyphenol/JJ
,/,
fiber/NN
,/,
calcium/NN
,/,
selenium/NN
,/,
and/CC
polyunsaturated/JJ
fatty/JJ
acids/NNS
(/(
e.g./FW
,/,
Omega-3/NNP
)/)
[/(
4/CD
]/)
./.
====================
Especially/RB
,/,
the/DT
environmental/JJ
factors/NNS
in/IN
cancer/NN
and/CC
a/DT
high/JJ
intake/NN
of/IN
vitamin/NN
B-complex/NN
play/VBP
important/JJ
roles/NNS
in/IN
DNA/NN
synthesis/NN
,/,
repair/NN
,/,
and/CC
methylation/NN
[/(
5/CD
]/)
./.
====================
There/EX
have/VBP
been/VBN
many/JJ
epidemiological/JJ
studies/NNS
that/IN
gastric/JJ
cancer/NN
is/VBZ
associated/VBN
with/IN
high-risk/JJ
dietary/JJ
profiles/NNS
(/(
low/JJ
folate/JJ
,/,
vitamin/NN
B6/NN
intake/JJ
,/,
and/CC
high/JJ
alcohol/NN
)/)
,/,
smoking/VBG
,/,
and/CC
low/JJ
blood/NN
folate/JJ
concentration/NN
[/(
6-8/CD
]/)
./.
====================
Folate/NN
is/VBZ
the/DT
water-soluble/JJ
form/VBP
of/IN
vitamin/NN
B9/NN
in/IN
foods/NNS
[/(
9/CD
]/)
./.
====================
Leafy/RB
vegetables/NNS
,/,
such/JJ
as/IN
spinach/DT
,/,
turnip/NN
greens/NNS
,/,
lettuces/VBZ
,/,
dried/VBN
beans/NNS
,/,
peas/IN
,/,
fortified/VBD
cereal/JJ
products/NNS
,/,
sunflower/JJR
seeds/VBZ
,/,
and/CC
certain/JJ
fruits/NNS
,/,
are/VBP
rich/JJ
sources/NNS
of/IN
folate/JJ
./.
====================
The/DT
recommended/JJ
dietary/JJ
allowance/NN
for/IN
adults/NNS
is/VBZ
400/CD
µg/VBG
of/IN
food/NN
folate/JJ
a/DT
day/NN
,/,
which/WDT
is/VBZ
equivalent/JJ
to/TO
about/RB
240/CD
µg/NN
synthetic/JJ
folic/JJ
acid/NN
in/IN
supplements/NNS
or/CC
fortified/VBN
food/NN
./.
====================
Women/NNS
of/IN
child-bearing/VBG
age/NN
planning/VBG
a/DT
pregnancy/NN
should/MD
take/VB
400/CD
µg/VBG
synthetic/JJ
folic/JJ
acid/NN
daily/RB
in/IN
addition/NN
to/TO
their/PRP$
normal/JJ
dietary/JJ
intake/JJ
[/(
10/CD
,/,
11/CD
]/)
./.
====================
There/EX
is/VBZ
now/RB
substantial/JJ
data/NNS
to/TO
support/VB
an/DT
important/JJ
role/NN
for/IN
folate/JJ
in/IN
the/DT
prevention/NN
of/IN
neural/JJ
tube/NN
defects/NNS
(/(
NTDs/NNS
)/)
,/,
Down/NN
syndrome/NN
,/,
vascular/JJ
disease/NN
,/,
various/JJ
cancers/NNS
,/,
Alzheimer/NN
's/POS
disease/NN
,/,
cognitive/JJ
function/NN
,/,
and/CC
affective/JJ
disorders/NNS
[/(
12/CD
]/)
./.
====================
Cumulative/JJ
evidences/VBZ
suggest/VBP
that/IN
food/NN
containing/VBG
folate/JJ
decreases/VBZ
the/DT
risk/NN
of/IN
colorectal/JJ
,/,
pancreatic/JJ
,/,
and/CC
esophageal/JJ
cancers/NNS
[/(
13/CD
]/)
./.
====================
Also/RB
,/,
a/DT
western/NN
lifestyle/JJ
,/,
which/WDT
is/VBZ
associated/VBN
with/IN
high/JJ
total/JJ
caloric/JJ
or/CC
fat/JJ
intake/JJ
(/(
include/VBP
red/JJ
meat/NN
)/)
,/,
and/CC
inactive/JJ
life/NN
pattern/NN
,/,
has/VBZ
been/VBN
considered/VBN
one/CD
of/IN
the/DT
main/JJ
reasons/NNS
for/IN
increasing/VBG
trends/NNS
of/IN
cancer/NN
in/IN
Koreans/NNS
[/(
14/CD
]/)
./.
====================
Variations/NNS
in/IN
levels/NNS
of/IN
serum/NN
total/JJ
homocysteine/NN
(/(
tHcy/NN
)/)
can/MD
result/VB
from/IN
genetic/JJ
or/CC
nutrient-related/JJ
disturbances/NNS
in/IN
the/DT
folate/JJ
pathway/NN
./.
====================
In/IN
this/DT
mechanism/NN
,/,
fasting/VBG
levels/NNS
of/IN
tHcy/NN
mainly/RB
reflect/VBP
the/DT
remethylation/NN
pathway/NN
./.
====================
In/IN
the/DT
remethylation/NN
pathway/NN
,/,
the/DT
primary/JJ
methyl/NN
donor/NN
for/IN
the/DT
vitamin/NN
B12-dependent/JJ
conversion/NN
of/IN
Hcy/NN
to/TO
methionine/JJ
is/VBZ
5-methlytetrahydrofolate/JJ
,/,
which/WDT
in/IN
turn/NN
forms/VBZ
5/CD
,/,
10-methlytetrahydrofolate/JJ
by/IN
means/NNS
of/IN
the/DT
enzyme/NN
methylenetetrahydrofolate/NN
reductase/NN
(/(
MTHFR/NN
)/)
./.
====================
Recent/JJ
reports/NNS
suggested/VBD
that/IN
individual/JJ
genetic/JJ
variation/NN
or/CC
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
in/IN
various/JJ
genes/NNS
involved/VBN
in/IN
cellular/JJ
folate/NN
metabolism/NN
or/CC
transport/VBP
may/MD
also/RB
be/VB
implicated/VBN
in/IN
cancer/NN
risk/NN
./.
====================
In/IN
the/DT
folate/JJ
metabolism/NN
pathway/NN
,/,
cellular/JJ
folate/NN
act/VBP
as/IN
donors/NNS
and/CC
receptors/NNS
of/IN
methyl/JJ
groups/NNS
in/IN
the/DT
biosynthesis/NN
of/IN
nucleotide/JJ
precursors/NNS
used/VBN
for/IN
DNA/NN
synthesis/NN
and/CC
provide/VBP
methyl/JJ
groups/NNS
for/IN
methylation/NN
of/IN
DNA/NN
,/,
RNA/NN
,/,
and/CC
proteins/NNS
[/(
15/CD
]/)
./.
====================
MTHFR/NN
,/,
methyltetrahydrofolate-homocysteine/NN
methyltransferase/NN
reductase/NN
(/(
MTRR/NN
)/)
,/,
and/CC
methyltetrahydrofolate-homocysteine/NN
methyltransferase/NN
(/(
MTR/NN
)/)
genes/NNS
are/VBP
well/RB
known/VBN
for/IN
their/PRP$
association/NN
with/IN
the/DT
folate/JJ
pathway/NN
[/(
16,17/CD
]/)
./.
====================
MTHFR/NN
maps/VBZ
to/TO
chromosome/NN
1p36.3/NN
and/CC
is/VBZ
2.2-kb/JJ
long/JJ
and/CC
contains/VBZ
11/CD
exons/NNS
./.
====================
The/DT
gene/NN
product/NN
is/VBZ
a/DT
77-kD/JJ
protein/NN
,/,
although/IN
a/DT
smaller/JJR
isoform/NN
of/IN
approximately/RB
70/CD
kD/NN
has/VBZ
been/VBN
observed/VBN
in/IN
some/DT
tissues/NNS
,/,
such/JJ
as/IN
liver/NN
[/(
18/CD
]/)
./.
====================
SNPs/NNS
in/IN
MTHFR/NN
,/,
such/JJ
as/IN
C677T/JJ
(/(
rs1801133/CD
)/)
,/,
A1298C/NN
(/(
rs1801131/NN
)/)
,/,
and/CC
G1793A/NN
(/(
rs2274976/NN
)/)
,/,
have/VBP
been/VBN
suggested/VBN
to/TO
be/VB
associated/VBN
with/IN
several/JJ
cancers/NNS
(/(
colon/NN
,/,
gastric/JJ
,/,
and/CC
breast/NN
)/)
,/,
cardiovascular/JJ
disease/NN
,/,
NTDs/NNS
,/,
and/CC
pregnancy/NN
complications/NNS
[/(
6/CD
,/,
9/CD
,/,
19-21/CD
]/)
./.
====================
In/IN
cancer/NN
patients/NNS
,/,
higher/JJR
sensitivity/NN
to/TO
5-fluorouracil/JJ
(/(
5-FU/NN
)/)
among/IN
patients/NNS
carrying/VBG
the/DT
MTHFR/NN
677TT/NN
and/CC
1298AA/NN
genotypes/NNS
compared/VBN
to/TO
the/DT
others/NNS
was/VBD
reported/VBN
,/,
demonstrating/VBG
a/DT
strong/JJ
predictive/JJ
ability/NN
of/IN
these/DT
polymorphisms/NNS
in/IN
response/NN
to/TO
5-FU-based/JJ
chemotherapy/NN
in/IN
gastric/JJ
cancer/NN
[/(
22/CD
,/,
23/CD
]/)
./.
====================
The/DT
MTRR/NN
gene/NN
was/VBD
mapped/VBN
to/TO
human/JJ
chromosome/NN
5p15.3-p15.2/CD
,/,
is/VBZ
34/CD
kb/NN
long/JJ
,/,
comprises/VBZ
15/CD
exons/NNS
,/,
has/VBZ
22/CD
codon/NN
SNP/NN
(/(
cSNP/NN
)/)
variation/NN
sites/NNS
,/,
and/CC
is/VBZ
thought/VBN
to/TO
produce/VB
cytosolic/JJ
and/CC
mitochondrial/JJ
mRNA/NN
isoforms/NNS
[/(
24/CD
,/,
25/CD
]/)
./.
====================
Polymorphisms/NNS
in/IN
MTRR-rs1801394/NN
(/(
A66G/NN
)/)
,/,
rs1532268/NN
(/(
S175L/NN
)/)
,/,
and/CC
rs10380/NN
(/(
H595Y/NN
)/)
-have/JJ
been/VBN
associated/VBN
with/IN
the/DT
risk/NN
of/IN
cancers/NNS
(/(
breast/NN
,/,
colon/NN
,/,
prostate/NN
,/,
pancreatic/JJ
,/,
and/CC
acute/JJ
lymphoblastic/JJ
leukemia/NN
)/)
,/,
Down/NN
syndrome/NN
,/,
and/CC
Alzheimer/NN
disease/NN
[/(
26-31/CD
]/)
./.
====================
The/DT
MTR/NN
gene/NN
maps/VBZ
to/TO
human/JJ
chromosome/NN
1q42/NN
,/,
is/VBZ
105/CD
kb/NN
,/,
comprises/VBZ
33/CD
exons/NNS
,/,
and/CC
has/VBZ
116/CD
SNP/NN
variation/NN
sites/NNS
./.
====================
One/CD
polymorphism/NN
in/IN
MTR/NN
(/(
rs1805087/NN
)/)
has/VBZ
been/VBN
associated/VBN
with/IN
colorectal/JJ
cancer/NN
and/CC
non-Hodgkin/JJ
lymphoma/NN
risk/NN
[/(
8/CD
,/,
32/CD
]/)
./.
====================
For/IN
gastric/JJ
cancer/NN
,/,
a/DT
genetic/JJ
variation/NN
in/IN
MTHFR/NN
has/VBZ
been/VBN
recently/RB
reported/VBN
[/(
33/CD
,/,
34/CD
]/)
./.
====================
Also/RB
,/,
case-control/JJ
studies/NNS
with/IN
specific/JJ
results/NNS
on/IN
folate/JJ
intake/JJ
(/(
or/CC
blood/NN
concentration/NN
)/)
and/CC
gastric/JJ
cancer/NN
risk/NN
suggest/VBP
a/DT
protective/JJ
role/NN
in/IN
a/DT
couple/JJ
of/IN
reports/NNS
[/(
35/CD
,/,
36/CD
]/)
./.
====================
The/DT
MTR/NN
or/CC
MTRR/NN
gene/NN
variations/NNS
were/VBD
associated/VBN
with/IN
colorectal/JJ
and/CC
pancreatic/JJ
cancer/NN
risk/NN
[/(
8/CD
,/,
37/CD
]/)
,/,
but/CC
there/EX
has/VBZ
been/VBN
no/DT
report/NN
on/IN
gastric/JJ
cancer/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
investigated/VBD
the/DT
association/NN
between/IN
polymorphisms/NNS
in/IN
MTHFR/NN
,/,
MTRR/NN
,/,
and/CC
MTR/NN
and/CC
the/DT
risk/NN
of/IN
gastric/JJ
cancer/NN
in/IN
Koreans/NNS
./.
====================
Clinical/JJ
samples/NNS
====================
Buffy/DT
coat/NN
samples/NNS
of/IN
1,261/NN
patients/NNS
(/(
69.4/CD
%/NN
)/)
who/WP
had/VBD
undergone/RB
surgery/NN
at/IN
the/DT
Gastric/JJ
Cancer/NN
Center/NN
,/,
National/JJ
Cancer/NN
Center/NN
(/(
NCC/NN
)/)
of/IN
Korea/NN
,/,
between/IN
September/NN
2001/CD
and/CC
December/NN
2005/CD
were/VBD
included/VBN
as/IN
cases/NNS
./.
====================
Most/JJS
of/IN
the/DT
selected/VBN
gastric/JJ
cancer/NN
patients/NNS
possessed/VBD
distal/JJ
stomach/NN
tumors/NNS
./.
====================
Archival/NN
375/CD
(/(
30.6/CD
%/NN
)/)
normal/JJ
buffy/JJ
coat/NN
samples/NNS
who/WP
had/VBD
joined/VBN
cancer/NN
screening/NN
examinees/NNS
from/IN
the/DT
NCC/NN
of/IN
Korea/NN
between/IN
August/NNP
2002/CD
and/CC
December/NN
2005/CD
were/VBD
also/RB
included/VBD
as/IN
controls/NNS
in/IN
this/DT
study/NN
./.
====================
Specification/NN
of/IN
group/NN
is/VBZ
listed/VBN
in/IN
Table/JJ
1/CD
./.
====================
This/DT
study/NN
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
(/(
IRB/NN
)/)
of/IN
the/DT
NCC/NN
of/IN
Korea/NN
(/(
NCCNSH03-024/NN
)/)
./.
====================
DNA/NN
extraction/NN
and/CC
sample/NN
preparation/NN
====================
DNA/NN
was/VBD
extracted/VBN
from/IN
350/CD
µL/NN
of/IN
whole/JJ
blood/NN
using/VBG
the/DT
MagAttract/JJ
DNA/NN
Blood/NN
Midi/NN
M48/NN
Kit/NN
(/(
Qiagen/NN
,/,
Valencia/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
using/VBG
a/DT
Qiagen/NN
BioRobot/NNP
M48/NN
workstation/NN
,/,
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
protocols/NNS
automatically/RB
./.
====================
The/DT
purity/NN
and/CC
concentration/NN
of/IN
isolated/VBN
DNA/NN
were/VBD
determined/VBN
by/IN
a/DT
Nanodrop/JJ
ND-1000/CD
spectrophotometer/NN
(/(
Nanodrop/NN
Technologies/NNS
,/,
Wilmington/JJ
,/,
DE/NN
,/,
USA/NN
)/)
./.
====================
We/PRP
needed/VBD
more/RBR
detailed/JJ
quantity/NN
of/IN
each/DT
sample/NN
for/IN
genotyping/VBG
reaction/NN
;/:
so/RB
,/,
we/PRP
measured/VBD
the/DT
quantity/NN
of/IN
DNA/NN
using/VBG
the/DT
Quant-iT/JJ
PicoGreen/NN
dsDNA/JJ
assay/NN
kit/NN
(/(
Invitrogen/NN
,/,
Inc./NNP
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
made/VBD
a/DT
dry/JJ
plate/VBP
for/IN
genotyping/VBG
reactions/NNS
with/IN
10/CD
ng/NN
per/IN
well/RB
of/IN
384/CD
plates/VBZ
./.
====================
Primer/NN
selection/NN
and/CC
assay/NN
design/NN
====================
Seventeen/CD
SNPs/NNS
in/IN
MTHFR/NN
,/,
MTRR/NN
,/,
and/CC
MTR/NN
were/VBD
selected/VBN
,/,
covering/VBG
previously/RB
studied/VBN
SNPs/NNS
,/,
such/JJ
as/IN
C677T/NN
(/(
rs1801133/CD
)/)
and/CC
A1298C/NN
(/(
rs1801131/NN
)/)
in/IN
MTHFR/NN
[/(
29/CD
]/)
and/CC
A66G/NN
(/(
rs1801394/NN
)/)
in/IN
MTR/NN
[/(
27/CD
]/)
./.
====================
The/DT
SNP/NN
information/NN
,/,
including/VBG
nucleic/JJ
acid/NN
sequences/NNS
,/,
was/VBD
collected/VBN
from/IN
dbSNP/NN
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/projects/SNP//JJ
;/:
Build/JJ
136/CD
)/)
./.
====================
SNPs/NNS
in/IN
coding/VBG
regions/NNS
and/CC
promoters/NNS
were/VBD
chosen/NN
at/IN
first/JJ
./.
====================
Regulatory/JJ
SNPs/NNS
with/IN
validated/JJ
allele/NN
frequency/NN
and/CC
nonsynonymous/JJ
cSNPs/NNS
were/VBD
finally/RB
included/VBD
./.
====================
Multiplexed/JJ
PCR/NN
primers/NNS
were/VBD
designed/VBN
for/IN
the/DT
best/JJS
PCR/NN
reaction/NN
and/CC
designed/VBN
for/IN
evading/VBG
the/DT
biophysical/JJ
hurdle/JJ
-/:
secondary/JJ
structure/NN
,/,
self-ligation/NN
,/,
competition/NN
of/IN
primers/NNS
,/,
etc/JJ
./.
====================
-/:
using/VBG
MassARRAY/NN
Assay/NN
Designer/NN
version/NN
3.0/CD
(/(
Sequenom/NN
,/,
Inc./NNP
,/,
San/JJ
Diego/NN
,/,
CA/NN
,/,
USA/NN
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
PCR/NN
amplification/NN
====================
PCR/NN
reactions/NNS
were/VBD
performed/VBN
in/IN
a/DT
total/JJ
volume/NN
of/IN
5/CD
µL/NN
with/IN
10/CD
ng/NN
of/IN
genomic/JJ
DNA/NN
,/,
1.625/CD
mM/NN
MgCl2/NN
,/,
0.1/CD
units/NNS
of/IN
HotStarTaq/NN
polymerase/NN
(/(
Qiagen/NN
)/)
,/,
0.5/CD
mM/NN
dNTPs/NNS
(/(
Invitrogen/NN
,/,
Inc./NNP
)/)
,/,
and/CC
100/CD
nM/NN
primers/NNS
./.
====================
The/DT
PCR/NN
reactions/NNS
started/VBD
at/IN
94℃/CD
for/IN
15/CD
min/NN
,/,
followed/VBN
by/IN
45/CD
cycles/NNS
of/IN
94℃/CD
for/IN
20/CD
s/NNS
,/,
50℃/CD
for/IN
30/CD
s/NNS
,/,
and/CC
72℃/CD
for/IN
1/CD
min/NN
,/,
with/IN
a/DT
final/JJ
extension/NN
of/IN
72℃/JJ
for/IN
3/CD
min/NN
./.
====================
Genotyping/VBG
====================
Genotyping/VBG
was/VBD
carried/VBN
out/RP
using/VBG
the/DT
iPLEX/NN
assay/NN
on/IN
the/DT
MassARRAY/NN
Platform/NN
(/(
Sequenom/NN
,/,
Inc./NNP
)/)
./.
====================
The/DT
iPLEX/NN
extension/NN
was/VBD
performed/VBN
in/IN
a/DT
total/JJ
volume/NN
of/IN
9/CD
µL/NN
with/IN
50/CD
µM/NN
dNTP/dideoxynucleotide/NN
phosphate/NN
(/(
ddNTP/NN
)/)
each/DT
,/,
0.063/CD
unit/µL/JJ
Thermo/DT
Sequenase/NN
(/(
Sequenom/NN
,/,
Inc./NNP
)/)
,/,
and/CC
625/CD
nM/NN
to/TO
1.25/CD
µM/NN
extension/NN
primers/NNS
./.
====================
iPLEX/NN
extension/NN
was/VBD
performed/VBN
using/VBG
2-step/JJ
200/CD
short-cycle/NN
programs/NNS
./.
====================
The/DT
sample/JJ
was/VBD
denatured/VBN
at/IN
94℃/CD
for/IN
5/CD
s/NNS
,/,
and/CC
strands/VBZ
were/VBD
annealed/VBN
at/IN
52℃/CD
for/IN
5/CD
s/NNS
and/CC
extended/VBD
at/IN
80℃/CD
for/IN
5/CD
s./CC
The/DT
annealing/JJ
and/CC
extension/NN
cycle/NN
was/VBD
repeated/VBN
4/CD
more/RBR
times/NNS
for/IN
a/DT
total/JJ
of/IN
5/CD
cycles/NNS
,/,
looped/VBD
back/RB
to/TO
a/DT
94℃/JJ
denaturing/VBG
step/NN
for/IN
5/CD
s/NNS
,/,
and/CC
then/RB
entered/VBD
the/DT
5-cycle/JJ
annealing/VBG
and/CC
extension/NN
loop/NN
again/RB
./.
====================
The/DT
5/CD
annealing/NN
and/CC
extension/NN
steps/NNS
with/IN
the/DT
single/JJ
denaturing/VBG
step/NN
were/VBD
repeated/VBN
an/DT
additional/JJ
39/CD
times/NNS
for/IN
a/DT
total/JJ
of/IN
40/CD
cycles/NNS
./.
====================
A/DT
final/JJ
extension/NN
was/VBD
done/VBN
at/IN
72℃/CD
for/IN
3/CD
min/NN
./.
====================
iPLEX/RB
extension/NN
products/NNS
were/VBD
desalted/VBN
by/IN
adding/VBG
6/CD
mg/NN
resin/NN
(/(
SpectroCLEAN/NN
;/:
Sequenom/NN
,/,
Inc./NNP
)/)
and/CC
16/CD
µL/NN
water/NN
./.
====================
After/IN
full/JJ
rotation/NN
in/IN
room/JJ
temperature/NN
,/,
the/DT
reaction/NN
mixture/NN
was/VBD
centrifuged/JJ
at/IN
3,500/CD
g/NN
,/,
5/CD
min/NN
./.
====================
After/IN
desalting/VBG
,/,
products/NNS
were/VBD
transferred/VBN
to/TO
SpectroCHIP/NN
using/VBG
a/DT
Nanodispenser/NN
(/(
SpectroPOINT/NN
;/:
Sequenom/NN
,/,
Inc./NNP
)/)
and/CC
then/RB
read/VBD
through/IN
matrix-assisted/JJ
laser/NN
desorption/ionization/NN
time-of-flight/JJ
(/(
SpectroReader/NN
;/:
Sequenom/NN
,/,
Inc./NNP
)/)
./.
====================
The/DT
resulting/VBG
genotype/NN
data/NNS
were/VBD
collected/VBN
by/IN
MassArray/NN
Typer/NN
software/JJ
version/NN
4.0/CD
(/(
Sequenom/NN
,/,
Inc./NNP
)/)
./.
====================
Statistical/JJ
analysis/NN
====================
The/DT
chi-square/NN
test/NN
for/IN
association/NN
was/VBD
used/VBN
to/TO
test/VB
differences/NNS
of/IN
genotype/NN
frequencies/NNS
between/IN
normal/JJ
and/CC
gastric/JJ
cancer/NN
patients/NNS
./.
====================
Odds/NNS
ratios/NNS
(/(
OR/NN
)/)
and/CC
their/PRP$
95/CD
%/NN
confidence/NN
intervals/NNS
(/(
CI/NN
)/)
in/IN
relation/NN
to/TO
MTHFR/NN
,/,
MTTRR/NN
,/,
and/CC
MTR/NN
genotypes/NNS
were/VBD
calculated/VBN
./.
====================
Also/RB
,/,
after/IN
adjustment/JJ
for/IN
sex/NN
,/,
family/NN
history/NN
,/,
smoking/NN
,/,
drinking/VBG
,/,
and/CC
H./NNP
pylori/NN
infection/NN
,/,
global/JJ
chi-square/NN
test/NN
was/VBD
also/RB
employed/VBN
to/TO
calculate/JJ
OR/NN
and/CC
their/PRP$
95/CD
%/NN
CIs/NNS
for/IN
individuals/NNS
./.
====================
Statistical/JJ
analyses/NNS
were/VBD
performed/VBN
using/VBG
SAS/NN
version/NN
9.0/CD
(/(
SAS/NN
Institute/JJ
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NN
)/)
./.
====================
Association/NN
between/IN
folate/JJ
pathway/NN
genes/NNS
and/CC
gastric/JJ
cancer/NN
risk/NN
====================
One/CD
thousand/CC
two/CD
hundred/JJ
sixty-one/NN
gastric/JJ
cancer/NN
patients/NNS
and/CC
375/CD
control/NN
groups/NNS
were/VBD
included/VBN
in/IN
the/DT
present/JJ
study/NN
./.
====================
From/IN
17/CD
SNPs/NNS
,/,
rs1476413/NN
,/,
rs2066470/NN
,/,
rs2274976/NN
,/,
rs3737964/NN
,/,
rs4846048/NN
,/,
rs7533315/NN
,/,
rs1805087/NN
,/,
rs1532268/NN
,/,
rs2303080/CD
,/,
rs162036/NN
,/,
rs2287780/CD
,/,
rs16879334/NN
,/,
and/CC
rs10380/NN
had/VBD
a/DT
minor/JJ
allele/NN
frequency/NN
less/RBR
than/IN
5/CD
%/NN
./.
====================
For/IN
each/DT
SNP/NN
,/,
the/DT
p-value/NN
of/IN
χ2-test/JJS
and/CC
OR/NN
were/VBD
calculated/VBN
(/(
Table/JJ
3/CD
)/)
./.
====================
Significant/JJ
associations/NNS
between/IN
genotypes/NNS
of/IN
folate/JJ
pathway/NN
SNPs/NNS
and/CC
the/DT
risk/NN
of/IN
gastric/JJ
cancer/NN
were/VBD
only/RB
observed/VBN
for/IN
rs1801394/NN
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
In/IN
rs1801394/NN
,/,
the/DT
frequencies/NNS
of/IN
the/DT
AG/NN
heterozygote/NN
genotype/NN
were/VBD
0.411/CD
and/CC
0.366/CD
in/IN
patients/NNS
and/CC
control/NN
groups/NNS
,/,
respectively/RB
./.
====================
The/DT
risk/NN
of/IN
gastric/JJ
cancer/NN
in/IN
patients/NNS
with/IN
the/DT
risk/NN
allele/NN
was/VBD
increased/VBN
as/IN
OR/NN
,/,
1.39/CD
(/(
codominant/JJ
model/NN
;/:
95/CD
%/NN
CI/NN
,/,
1.04/CD
to/TO
1.85/CD
)/)
or/CC
OR/NN
,/,
1.34/CD
(/(
dominant/JJ
model/NN
;/:
95/CD
%/NN
CI/NN
,/,
1.02/CD
to/TO
1.75/CD
)/)
with/IN
statistical/JJ
significance/NN
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
Association/NN
between/IN
folate/JJ
pathway/NN
genes/NNS
and/CC
obese/DT
gastric/JJ
cancer/NN
patients/NNS
====================
Further/RB
,/,
the/DT
association/NN
between/IN
the/DT
17/CD
SNPs/NNS
of/IN
folate/JJ
pathway/NN
genes/NNS
and/CC
gastric/JJ
cancer/NN
risk/NN
was/VBD
analyzed/VBN
and/CC
stratified/JJ
by/IN
obesity/NN
categories/NNS
(/(
BMI/NN
,/,
</JJR
25/CD
vs./CC
≥25/CD
)/)
(/(
Table/JJ
4/CD
)/)
./.
====================
Interestingly/RB
,/,
the/DT
risk/NN
of/IN
rs1801394/NN
was/VBD
dramatically/RB
increased/VBD
for/IN
the/DT
codominant/JJ
model/NN
(/(
OR/NN
,/,
9.08/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.01/CD
to/TO
94.59/CD
;/:
p/NN
</JJR
0.05/CD
)/)
only/RB
among/IN
obese/DT
subjects/NNS
./.
====================
For/IN
the/DT
dominant/JJ
model/NN
,/,
the/DT
OR/NN
was/VBD
also/RB
increased/VBD
with/IN
statistical/JJ
significance/NN
(/(
OR/NN
,/,
1.98/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.06/CD
to/TO
3.49/CD
;/:
p/NN
</JJR
0.05/CD
)/)
./.
====================
Also/RB
,/,
the/DT
recessive/JJ
model/NN
showed/VBD
significantly/RB
higher/JJR
risk/NN
(/(
OR/NN
,/,
3.72/CD
;/:
95/CD
%/NN
CI/NN
,/,
0.92/CD
to/TO
16.59/CD
)/)
./.
====================
Additionally/RB
,/,
we/PRP
analyzed/VBD
the/DT
correlation/NN
among/IN
family/NN
history/NN
,/,
H./NNP
pylori/NN
infection/NN
,/,
and/CC
folate/JJ
gene/NN
SNPs/NNS
but/CC
did/VBD
not/RB
find/VB
any/DT
significant/JJ
association/NN
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
For/IN
early/JJ
detection/NN
and/CC
diagnosis/NN
of/IN
cancer/NN
,/,
the/DT
discovery/NN
of/IN
new/JJ
biomarkers/NNS
is/VBZ
very/RB
important/JJ
,/,
and/CC
the/DT
interest/NN
of/IN
researchers/NNS
is/VBZ
growing/VBG
rapidly/RB
./.
====================
Also/RB
,/,
genetic/JJ
factors/NNS
,/,
including/VBG
polymorphisms/NNS
of/IN
genes/NNS
involved/VBN
in/IN
tumorigenesis/NN
,/,
may/MD
partly/RB
explain/VBP
the/DT
difference/NN
in/IN
individual/JJ
susceptibility/NN
to/TO
cancer/NN
[/(
38/CD
]/)
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
studied/VBD
the/DT
impact/NN
of/IN
folate/JJ
pathway/NN
gene/NN
polymorphisms/NNS
on/IN
the/DT
risk/NN
of/IN
gastric/JJ
cancer/NN
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
Since/IN
folic/JJ
acid/NN
was/VBD
a/DT
critical/JJ
cofactor/NN
in/IN
one-carbon/JJ
metabolism/NN
involving/VBG
in/IN
the/DT
biological/JJ
methylation/NN
and/CC
nucleotide/NN
synthesis/NN
pathways/NNS
,/,
our/PRP$
study/NN
may/MD
find/VB
clues/NNS
for/IN
the/DT
possible/JJ
effect/NN
to/TO
dietary/JJ
effects/NNS
on/IN
gastric/JJ
cancer/NN
./.
====================
In/IN
the/DT
report/NN
of/IN
previous/JJ
studies/NNS
,/,
the/DT
frequency/NN
of/IN
genotypes/NNS
for/IN
MTHFR/NN
was/VBD
similar/JJ
with/IN
our/PRP$
results-less/NN
than/IN
5/CD
%/NN
for/IN
many/JJ
SNPs/NNS
[/(
39/CD
,/,
40/CD
]/)
./.
====================
For/IN
MTHFR/NN
,/,
one/CD
study/NN
found/VBD
the/DT
association/NN
of/IN
rs1801133/NN
with/IN
gastric/JJ
cancer/NN
risk/NN
but/CC
no/DT
association/NN
of/IN
rs1801131/NN
[/(
34/CD
]/)
./.
====================
However/RB
,/,
different/JJ
results/NNS
have/VBP
been/VBN
reported/VBN
in/IN
other/JJ
studies/NNS
,/,
showing/VBG
no/DT
association/NN
for/IN
either/CC
SNP/NN
with/IN
gastric/JJ
cancer/NN
[/(
33/CD
]/)
./.
====================
We/PRP
also/RB
found/VBD
no/DT
association/NN
of/IN
either/CC
SNP/NN
with/IN
gastric/JJ
cancer/NN
risk/NN
,/,
which/WDT
is/VBZ
concordant/JJ
with/IN
the/DT
results/NNS
of/IN
Kim/NN
's/POS
group/NN
[/(
33/CD
]/)
./.
====================
For/IN
MTR/NN
,/,
although/IN
a/DT
couple/JJ
of/IN
reports/NNS
have/VBP
shown/VBN
a/DT
significant/JJ
association/NN
between/IN
the/DT
polymorphism/NN
of/IN
MTR/NN
and/CC
the/DT
risk/NN
of/IN
certain/JJ
cancers/NNS
[/(
32/CD
]/)
,/,
we/PRP
could/MD
not/RB
find/VB
any/DT
association/NN
in/IN
our/PRP$
study/NN
population/NN
of/IN
gastric/JJ
cancer/NN
./.
====================
In/IN
our/PRP$
study/NN
,/,
a/DT
significant/JJ
association/NN
of/IN
rs1801394/NN
(/(
A66G/NN
)/)
in/IN
MTRR/NN
was/VBD
found/VBN
,/,
especially/RB
with/IN
high/JJ
OR/NN
among/IN
the/DT
obese/JJ
gastric/JJ
cancer/NN
group/NN
./.
====================
MTRR/NN
regenerates/VBZ
a/DT
functional/JJ
methionine/NN
synthase/NN
via/IN
reductive/JJ
methylation/NN
so/RB
that/IN
methionine/NN
synthase/NN
can/MD
catalyze/VB
methionine/NN
synthesis/NN
,/,
which/WDT
is/VBZ
an/DT
essential/JJ
amino/NN
acid/NN
required/VBD
for/IN
protein/NN
synthesis/NN
and/CC
one-carbon/JJ
metabolism/NN
./.
====================
The/DT
A66G/NN
polymorphism/NN
is/VBZ
reported/VBN
to/TO
be/VB
functional/JJ
,/,
so/RB
that/IN
the/DT
variant/JJ
enzyme/NN
has/VBZ
a/DT
lower/JJR
affinity/NN
for/IN
MTR/NN
[/(
41/CD
]/)
./.
====================
A/DT
large/JJ
number/NN
of/IN
studies/NNS
have/VBP
been/VBN
conducted/VBN
to/TO
evaluate/VB
the/DT
role/NN
of/IN
rs1801394/NN
in/IN
different/JJ
kinds/NNS
of/IN
cancers/NNS
;/:
the/DT
results/NNS
are/VBP
still/RB
plausible/JJ
./.
====================
One/CD
meta-analysis/NN
reported/VBD
that/IN
the/DT
A66G/NN
polymorphism/NN
should/MD
contribute/VB
to/TO
tumor/NN
susceptibility/NN
,/,
showing/VBG
significantly/RB
increased/VBD
risk/NN
among/IN
Asians/NNS
with/IN
the/DT
G/NN
allele/NN
,/,
which/WDT
is/VBZ
also/RB
in/IN
concordance/NN
with/IN
our/PRP$
result/NN
[/(
42/CD
]/)
./.
====================
Our/PRP$
result/NN
is/VBZ
biologically/RB
plausible/JJ
,/,
since/IN
the/DT
polymorphisms/NNS
or/CC
gene-environment/JJ
interactions/NNS
,/,
rather/RB
than/IN
folate/JJ
intake/JJ
alone/RB
,/,
would/MD
have/VBP
an/DT
impact/NN
on/IN
the/DT
risk/NN
for/IN
digestive/JJ
track/VBP
cancer/NN
,/,
because/IN
functional/JJ
SNPs/NNS
in/IN
folate-related/JJ
genes/NNS
were/VBD
known/VBN
to/TO
contribute/VB
to/TO
the/DT
alteration/NN
of/IN
folate/JJ
metabolism/NN
[/(
30/CD
]/)
./.
====================
The/DT
SNPs/NNS
in/IN
folate/JJ
pathway/NN
genes/NNS
(/(
such/JJ
as/IN
MTHFR/NN
)/)
were/VBD
reported/VBN
to/TO
influence/VB
to/TO
the/DT
decrease/NN
of/IN
the/DT
activity/NN
of/IN
the/DT
enzyme/NN
,/,
leading/VBG
to/TO
hyperhomocysteinemia/NN
,/,
particularly/RB
in/IN
folate-deficient/JJ
states/NNS
[/(
43/CD
]/)
./.
====================
Homocysteine/NN
was/VBD
related/JJ
to/TO
cancer/NN
formation/NN
,/,
like/IN
tumor/NN
necrosis/NN
factor/NN
,/,
obesity/NN
,/,
and/CC
the/DT
folate/JJ
pathway/NN
,/,
and/CC
is/VBZ
known/VBN
to/TO
be/VB
one/CD
of/IN
the/DT
main/JJ
risk/NN
factors/NNS
for/IN
distal/JJ
gastric/JJ
cancer/NN
,/,
including/VBG
H./NNP
pylori/NN
infection/NN
and/CC
dietary/JJ
factors/NNS
[/(
44/CD
]/)
./.
====================
Although/IN
obesity/NN
(/(
BMI/NN
>/JJR
25/CD
)/)
was/VBD
more/RBR
prevalent/JJ
in/IN
patients/NNS
with/IN
cardia/NN
cancer/NN
compared/VBN
to/TO
patients/NNS
with/IN
gastric/JJ
distal/JJ
cancer/NN
in/IN
Koreans/NNS
[/(
45/CD
]/)
,/,
a/DT
previous/JJ
study/NN
reported/VBD
that/IN
obesity/NN
is/VBZ
a/DT
major/JJ
risk/NN
factor/NN
for/IN
several/JJ
types/NNS
of/IN
cancer/NN
,/,
including/VBG
gastric/JJ
cancer/NN
[/(
46/CD
]/)
./.
====================
Also/RB
,/,
many/JJ
epidemiological/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
obesity/NN
is/VBZ
a/DT
risk/NN
factor/NN
for/IN
breast/NN
cancer/NN
,/,
colon/NN
and/CC
kidney/NN
cancer/NN
,/,
and/CC
malignant/JJ
adenomas/NNS
of/IN
the/DT
esophagus/NN
./.
====================
Obesity/NN
subjects/NNS
have/VBP
an/DT
approximately/RB
1.5-3.5-fold/RB
increased/VBD
risk/NN
of/IN
developing/VBG
these/DT
cancers/NNS
compared/VBN
with/IN
normal-weight/JJ
subjects/NNS
[/(
47/CD
]/)
./.
====================
Here/RB
,/,
we/PRP
report/VBP
the/DT
association/NN
of/IN
genetic/JJ
variations/NNS
in/IN
MTRR/NN
with/IN
the/DT
risk/NN
of/IN
gastric/JJ
cancer/NN
for/IN
the/DT
first/JJ
time/NN
./.
====================
In/IN
further/JJ
studies/NNS
,/,
we/PRP
need/VBD
to/TO
validate/VB
our/PRP$
finding/NN
in/IN
a/DT
larger/RBR
population/NN
,/,
considering/VBG
detailed/JJ
clinical/JJ
information/NN
,/,
and/CC
study/NN
the/DT
functional/JJ
relevance/NN
of/IN
polymorphisms/NNS
with/IN
cancer/NN
development/NN
more/RBR
./.
====================
Also/RB
,/,
we/PRP
need/VBD
to/TO
consider/VB
other/JJ
genes/NNS
in/IN
the/DT
folate/JJ
pathway/NN
and/CC
investigate/VB
gastric/JJ
cancer/NN
susceptibility/NN
with/IN
epidemiological/JJ
and/CC
environmental/JJ
factors/NNS
(/(
e.g./FW
,/,
nutrition/NN
intake/JJ
,/,
5-FU/NN
drug/NN
interference/NN
,/,
blood/NN
folate/JJ
concentration/NN
,/,
etc/JJ
./.
)/)
./.
====================
Description/NN
of/IN
the/DT
case/NN
and/CC
control/NN
group/NN
====================
Primers/NNS
used/VBN
for/IN
the/DT
genotyping/VBG
of/IN
polymorphisms/NNS
in/IN
folate/JJ
metabolic/JJ
pathway/NN
genes/NNS
====================
Association/NN
between/IN
the/DT
folate/JJ
pathway/NN
polymorphisms/NNS
and/CC
gastric/JJ
cancer/NN
patient/NN
risk/NN
,/,
ORa/NN
value/NN
(/(
95/CD
%/NN
confidence/NN
intervals/NNS
)/)
====================
Association/NN
between/IN
the/DT
folate/JJ
pathway/NN
polymorphisms/NNS
for/IN
gastric/JJ
cancer/NN
risk/NN
by/IN
obesity/NN
,/,
ORa/NN
value/NN
(/(
95/CD
%/NN
confidence/NN
intervals/NNS
)/)
====================
